SOPHiA GENETICS grants options and RSUs to CPO

SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards tied to her role.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards tied to her role. She was granted share options for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units (RSUs), each representing one ordinary share upon vesting.

According to the vesting terms, 25% of the RSUs will vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, conditioned on continued service. The share options vest as to 25% on April 2, 2027, then in equal monthly installments through April 2, 2030.

Insider Trade Summary

Grant/Award: 176,659 shares

Grant/Award 2 txns

Insider Valente Manuela

Role Chief People Officer

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	104,790	$0.00	$0.00
Grant/Award	Ordinary Shares	71,869	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 104,790 contracts (Direct); Ordinary Shares — 71,869 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
2. F2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Key Figures

Share options granted: 104,790 options Option exercise price: $5.04 per share Option expiration: April 2, 2036 +4 more

7 metrics

Share options granted 104,790 options Grant on April 2, 2026 to Chief People Officer

Option exercise price $5.04 per share Exercise price for granted share options

Option expiration April 2, 2036 Expiration date of share options

RSUs granted 71,869 RSUs Restricted stock unit grant on April 2, 2026

Initial RSU vesting 25% on April 2, 2027 First RSU vesting tranche subject to continued service

Remaining RSU vesting 75% through April 2, 2030 Quarterly RSU vesting installments after initial cliff

Option vesting schedule 25% on April 2, 2027 Share options then vest monthly through April 2, 2030

Key Terms

restricted stock unit ("RSU"), 2021 Equity Incentive Plan, vesting, share option, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan."

2021 Equity Incentive Plan financial

"RSU grant made under the Issuer's 2021 Equity Incentive Plan."

vesting financial

"25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

share option financial

"The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027."

exercise price financial

"conversion_or_exercise_price": "5.0400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did SOPHiA GENETICS (SOPH) grant to Manuela Valente?

SOPHiA GENETICS granted Chief People Officer Manuela Valente share options and RSUs. She received options for 104,790 ordinary shares at a $5.04 exercise price and 71,869 restricted stock units, all awarded as compensation tied to continued service.

How do the RSUs granted to Manuela Valente at SOPHiA GENETICS (SOPH) vest?

The RSUs vest over several years based on continued service. Twenty-five percent vest on April 2, 2027, and the remaining seventy-five percent vest in equal quarterly installments through April 2, 2030, each RSU settling into one ordinary share when vested.

What are the vesting terms of the SOPHiA GENETICS (SOPH) share options granted to Manuela Valente?

The share options vest gradually over time. Twenty-five percent of the underlying ordinary shares vest on April 2, 2027, with the remaining options vesting in equal monthly installments through April 2, 2030, aligning long-term incentives with ongoing employment.

What is the exercise price and expiration date of Manuela Valente’s SOPHiA GENETICS (SOPH) options?

The granted share options have a fixed exercise price of $5.04 per ordinary share. These options expire on April 2, 2036, giving a long window for potential exercise once vested, subject to standard plan and service conditions.

Are the SOPHiA GENETICS (SOPH) RSU and option grants to Manuela Valente open-market purchases?

No, both awards are compensation grants, not market purchases. The Form 4 shows transaction code “A” for grant or award acquisition, with a reported price of $0.00, reflecting issuance under the company’s 2021 Equity Incentive Plan rather than cash buying.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/03/2026 - 06:58 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valente Manuela

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/02/2026		A		71,869(1)	A	$0	71,869	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$5.04	04/02/2026		A		104,790		(2)	04/02/2036	Ordinary Shares	104,790	$0	104,790	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.

2. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Manuela Valente	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)